middle.news
Alterity Therapeutics Secures A$20M to Propel ATH434 Toward FDA Approval
9:53am on Monday 8th of September, 2025 AEST
•
Healthcare
Read Story
Alterity Therapeutics Secures A$20M to Propel ATH434 Toward FDA Approval
9:53am on Monday 8th of September, 2025 AEST
Key Points
A$20 million capital raise via placement at 7.7% discount
Funds to support ATH434 clinical, regulatory, and manufacturing activities
Placement anchored by a high-quality international healthcare fund
Positive Phase 2 trial data underpinning regulatory engagement plans
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Alterity Therapeutics (ASX:ATH)
OPEN ARTICLE